REGEN-COV Available – New Antibody Treatment for COVID-19

REGEN-COV Available

REGEN-COV: Available Now!

REGEN-COV (casirivimab and imdevimab) is an FDA approved investigational medicine antibody treatment for COVID-19.

Find out about REGEN-COV and what this means to you.

About REGEN-COV, What it Means to You and Your Family

What Is REGEN-COV?

Casirivimab/imdevimab, sold under the brand name REGEN-COV is an FDA-authorized investigational medicine antibody therapy for the treatment of mild to moderate COVID-19 in adults and adolescents (12 years of age and older who weigh at least 88 pounds (40kg) who are at high risk for severe COVID-19. Source: Regeneron

How Does REGEN-COV therapy work?

REGEN-COV is an antibody cocktail that combines two monoclonal antibodies: casirivimab and imdevimab. 

These two man-made monoclonal antibodies were designed to produce resistance against the SARS-CoV-2, the coronavirus that causes COVID-19.

When infected with a virus such as SARS-CoV2, which causes COVID-19, our immune system reacts by creating antibodies to fight it off. However, it takes time for our immune system to make antibodies, and in the meantime, we could get gravely sick.

REGEN-COV contains man-made antibodies that are very similar to the antibodies of recovered COVID-19 patients. By injecting these antibodies or administrating them, we can give our immune system a head start and allow it sufficient time to create our own antibodies.

It’s important to know that REGEN-COV does not have any COVID-19 virus in it.

Who Qualifies for This New Antibody Therapy?

REGEN-COV is not for everyone.

REGEN-COV is a U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization.

Patients must be 12 years of age or older and patients must weigh at least 88 pounds. The list of potential qualifying individuals includes those 65 years of age and older and patients with certain chronic medical conditions.

Who are at High Risk for Severe COVID-19 Complications?

The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg) at higher risk for progression to severe COVID-19:

  • – Older age (for example, age ≥65 years of age)
  • – Obesity or being overweight (for example, BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender-based on CDC growth charts
  • – Pregnancy
  • – Chronic kidney disease
  • – Diabetes
  • – Immunosuppressive disease or immunosuppressive treatment
  • – Cardiovascular disease (including congenital heart disease) or hypertension
  • – Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
  • – Sickle cell disease
  • – Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
  • – Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID 19))

Tell your healthcare provider about all of your medical conditions, including if you:

  • – Have any allergies
  • – Have had a severe allergic reaction including anaphylaxis to REGEN-COV previously
  • – Have received a COVID-19 vaccine
  • – Have any serious illnesses
  • – Are pregnant or plan to become pregnant
  • – Are breastfeeding or plan to breastfeed
  • – Are taking any medications (prescriptions, over-the-counter drugs, vitamins, and herbal products)

Doctor Screenings

While not all patients will qualify for the treatment, doctors at Altus Emergency Centers and Lumberton Hospital will provide medical screening for any COVID-19 patient.

If our doctors determine you are a candidate for REGEN-COV therapy, then they will issue the therapeutic and administer it while being a patient in our facility.

COVID-19 Emergency

This therapeutic medication is for our patients receiving emergency services. When a patient comes into our facility for a COVID-19 emergency, they will have the opportunity to receive REGEN-COV if they meet the criteria.

As in all medications, please feel free to consult with the physician as to a potential list of side effects.

FDA Approved Investigational Therapy

REGEN-COV is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using REGEN-COV to treat people with COVID-19 or to prevent COVID-19 in people who are at high risk of being exposed to someone who is infected with SARS-CoV-2. REGEN-COV is not authorized for pre-exposure prophylaxis for the prevention of COVID-19.

Source: Regeneron

DISCLAIMER

COVID-19 Emergency This therapeutic medication is for our patients receiving emergency services. When a patient comes into our facility for a COVID-19 emergency, they will have the opportunity to receive REGEN-COV if they are positive for Covid-19 and meet the criteria set. As in all medications, please feel free to consult with the physician as to a potential list of side effects.

Menu